Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain.

Schweikert, Bernd; Malmberg, Chiara; Núñez, Mercedes; Dilla, Tatiana; Sapin, Christophe; Hartz, Susanne

Schweikert, Bernd; Malmberg, Chiara; Núñez, Mercedes; Dilla, Tatiana; Sapin, Christophe; Hartz, Susanne.

Afiliação

Schweikert B; Real World Evidence Strategy and Analytics, Commercialisation and Outcomes, ICON, Munich, Germany Bernd.Schweikert@iconplc.com.
Malmberg C; Access, Commercialisation and Communications, ICON, Munich, Germany.
Núñez M; Health Outcomes and Real World Evidence, Eli Lilly and Company, Madrid, Spain.
Dilla T; Global Patient Outcomes and Real World Evidence International, Eli Lilly and Company, Madrid, Spain.
Sapin C; European Statistics, Eli Lilly and Company, Neuilly-sur-Seine, France.
Hartz S; Global Patient Outcomes and Real World Evidence International, Eli Lilly and Company, Windlesham, UK.

BMJ Open ; 10(8): e032552, 2020 08 13.

Article em En | MEDLINE | ID: mdl-32792421

Assuntos

Artrite Psoriásica; Psoríase; Anticorpos Monoclonais/uso terapêutico; Anticorpos Monoclonais Humanizados; Artrite Psoriásica/tratamento farmacológico; Análise Custo-Benefício; Humanos; Cadeias de Markov; Metanálise em Rede; Psoríase/tratamento farmacológico; Espanha

Palavras-chave

Spanish population; biologics; cost-effectiveness analysis; ixekizumab; psoriatic arthritis; secukinumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / Artrite Psoriásica Tipo de estudo: Health_economic_evaluation / Prognostic_studies Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google